Month: May 2021

  • How a netball protegee became an MD

    • 28 May 2021

    Astellas MD Lizzie Marett dreamed of playing netball for New Zealand. When that didn’t work out, she started on a path that has led her around the world and into her current role.

    Read more
  • Hunt prevents June PBS delisting

    • 28 May 2021

    Health Minister Greg Hunt has stepped in to persuade a generics manufacturer to seek a price increase rather than delist multiple brands of an important women’s hormonal product.

    Read more
  • Roche to delist another blockbuster

    • 28 May 2021

    Another cancer blockbuster preps for delisting as Roche again names price as the catalyst. This time the biosimilars aren’t even administered the same way.

    Read more
  • GSK’s Boronia site eyed for mRNA

    • 28 May 2021

    Charter Hall purchases GSK site as former GSK regional head is reported to be negotiating to lease the site for mRNA vaccine production.

    Read more
  • From one David to another, GSK is in good hands

    • 26 May 2021

    David Pullar had big shoes to fill when he took on the Communications, Government Affairs and Market Access Director role at GSK earlier this year, replacing industry stalwart David Herd. He talks to MedNews about putting his own stamp on the role.

    Read more
  • JAKs duke it out for Humira territory

    • 26 May 2021

    Pfizer’s successful complaint against AbbVie fuels industry concerns about the practical application of the new principles-based Code.

    Read more
  • Aussies access Biogen ALS drug

    • 26 May 2021

    Biogen is looking to provide early and compassionate access to some ALS patients later this year, with Australians in the line-up.

    Read more
  • Is Europe ready for gene therapies?

    • 26 May 2021

    Novartis report questions whether Europe’s regulator is ready for gene therapies as the EMA considers bluebird bio’s cALD gene therapy.

    Read more